AstraZeneca has emphasized the safety profile of its COVID-19 vaccine after rare side effects were reported. The company recently admitted that its Covishield and Vaxzevria vaccines can cause Thrombosis Thrombocytopenia Syndrome in rare cases. However, AstraZeneca maintains that extensive clinical trial data and real-world evidence consistently support the overall safety and efficacy of the vaccine. The vaccine, known as Covishield in India, has been widely used and no serious concerns have been reported. AstraZeneca made this admission in court documents related to a case alleging vaccine-related deaths and injuries.